2016 ASCO Annual Meeting - ASCO


Powered by SmugMug Log In
Charles M. Rudin, MD, PhD, presenting LBA8505, Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC) during Lung Cancer? Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Oral Abstract Session

Charles M. Rudin, MD, PhD, presenting LBA8505, Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC) during Lung Cancer? Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Oral Abstract Session

Chicago, IL - 2016 ASCO Annual Meeting - Charles M. Rudin, MD, PhD, presenting LBA8505, Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC) during Lung Cancer? Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Oral Abstract Session at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Sunday, June 5, 2016. Over 30,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 52nd Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Max Gersh 2016 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org